LOUISVILLE, Colo., March 1 /PRNewswire-FirstCall/ -- Replidyne, Inc. announced today that Chief Scientific Officer and Co-founder, Nebojsa Janjic, Ph.D., will give a company presentation at the Leerink Swann & Company/MEDACorp Roundtable conference titled, Catching the Bug for Novel Antibiotics. The presentation will take place at 11:15am ET on Tuesday, March 6, 2007 at Le Parker Meridien Hotel in New York City.
A live audio webcast of Replidyne’s presentation will be available on the investor relations section of the company’s website at www.Replidyne.com. The webcast will be archived and available on Replidyne’s website after the event for a period of 30 days.
About Replidyne, Inc.
Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne’s lead product, faropenem medoxomil, is a novel oral, community antibiotic, expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne’s second drug candidate, REP8839, is a topical anti-infective product under Phase I development for the treatment of skin and wound infections, including methicillin resistant S. aureus (MRSA) infections. Replidyne is also pursuing the development of other novel anti-infective products based on its in-house discovery research.
Replidyne, Inc.
CONTACT: Sabrina B. Oei, Dir. Investor & Public Relations of Replidyne,+1-303-996-5535
Web site: http://www.Replidyne.com/
